Shipments to Brazil commence

Oxford Pharmascience Group Plc

("Oxford Pharmascience" or "the Company")

Shipments of first product to Brazilian pharmaceutical company commence

Oxford Pharmascience, the speciality pharmaceutical company that uses advanced drug delivery technologies to reposition medicines, is pleased to announce that following the entering into of an exclusive licensing and distribution agreement earlier this year with Aché Laboratórios Farmacêuticos S.A., ("Aché"), the Company has commenced shipments of its first product to Brazil. A first order with a value of c £105,000 has been produced and dispatched to Brazil in advance of trade sales which are planned to commence later in the year. Ache is one of Brazil's largest pharmaceutical companies distributing over 250 brands of prescription and generic drugs and OTC products.

Under the terms of the seven year agreement, Oxford Pharmascience will supply Aché with healthcare products which will be sold under a new women's health brand, called 'Inellare'. The first product is a Calcium and Vitamin D product based on Oxford Pharmascience's solid state suspension technology which allows for superior taste masking and very rapid dissolution of active ingredients. Laboratory dissolution tests have demonstrated significant improvements in dissolution of this system relative to standard calcium tablets and chewable tablets.

It is anticipated that Oxford Pharmascience, using its own intellectual property, will develop a number of pharmaceutical products for Aché, as the Brazilian pharmaceutical company expands its 'Inellare' product range. The Company has begun testing several concepts in Brazil to expand the range following the launch of the initial first product.

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

ZAI Corporate Finance (Nominated Adviser)

John Depasquale +44 20 7060 2220

Sarang Shah +44 20 7060 2220

Hybridan LLP (Broker)

Claire Noyce +44 20 7947 4350

About Oxford Pharmascience Group Plc

-- Oxford Pharmascience are specialists in the repositioning of medicines via reformulation using advanced pharmaceutic technologies adding value to generic and soon to be off patent Active Pharmaceutical Ingredients (API's), -- Technology portfolio includes superior chewable tablets, liquid suspensions, and solid state suspensions (soft chews) as well as modified drug delivery technologies to achieve either taste masking or targeted release effects.

-- The Company uses its technologies to develop Drug Master Files (DMF's) and full CTD dossiers (drug registration dossiers) for a range of medicines initially with focus on NSAIDs, statins and calcium.

-- Oxford Pharmascience works closely with leading academic institutions to further advance its intellectual property portfolio to apply to generic and soon to be generic drugs.

About Aché Laboratórios Farmacêuticos S.A., ("Aché")

-- Established 40 years ago, Ache is the largest fully Brazilian owned pharmaceutical company and currently distributes over 250 brands of prescription and generic drugs and OTC products.

-- During 2009 Ache had sales revenue of over GBP780 million (R$2,157 million).

-- Ache's sales force makes approximately 30,000 visits to physicians a year.

- Ends -